Compare IDCC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDCC | TVTX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.3B |
| IPO Year | 2007 | 2013 |
| Metric | IDCC | TVTX |
|---|---|---|
| Price | $325.80 | $53.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | ★ $462.67 | $75.21 |
| AVG Volume (30 Days) | 166.1K | ★ 1.6M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | $47.65 |
| Revenue Next Year | N/A | $49.39 |
| P/E Ratio | $60.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $249.14 | $22.59 |
| 52 Week High | $412.60 | $68.73 |
| Indicator | IDCC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 33.14 |
| Support Level | $317.76 | $41.75 |
| Resistance Level | $351.31 | $59.93 |
| Average True Range (ATR) | 9.64 | 2.23 |
| MACD | -0.76 | -0.59 |
| Stochastic Oscillator | 17.94 | 16.30 |
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.